181 related articles for article (PubMed ID: 27023593)
1. Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.
Bagaglio S; Andolina A; Merli M; Uberti-Foppa C; Morsica G
Viruses; 2016 Mar; 8(4):91. PubMed ID: 27023593
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E
J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
[TBL] [Abstract][Full Text] [Related]
7. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus.
Peres-da-Silva A; de Almeida AJ; Lampe E
J Antimicrob Chemother; 2015 Mar; 70(3):726-30. PubMed ID: 25414201
[TBL] [Abstract][Full Text] [Related]
8. Self-association and conformational variation of NS5A domain 1 of hepatitis C virus.
Beldar S; Manimekalai MSS; Cho NJ; Baek K; Grüber G; Yoon HS
J Gen Virol; 2018 Feb; 99(2):194-208. PubMed ID: 29300159
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
[TBL] [Abstract][Full Text] [Related]
11. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals.
Nguyen LT; Hall N; Sheerin D; Carr M; De Gascun CF;
Antivir Ther; 2016; 21(5):447-53. PubMed ID: 26789637
[TBL] [Abstract][Full Text] [Related]
12. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
Hernandez D; Zhou N; Ueland J; Monikowski A; McPhee F
J Clin Virol; 2013 May; 57(1):13-8. PubMed ID: 23384816
[TBL] [Abstract][Full Text] [Related]
13. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
[TBL] [Abstract][Full Text] [Related]
14. Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia.
Simicic P; Grgic I; Santak M; Vince A; Lepej SZ
Microb Pathog; 2019 Nov; 136():103694. PubMed ID: 31446041
[TBL] [Abstract][Full Text] [Related]
15. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
[TBL] [Abstract][Full Text] [Related]
16. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.
Pham LV; Ramirez S; Carlsen THR; Li YP; Gottwein JM; Bukh J
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348150
[TBL] [Abstract][Full Text] [Related]
17. Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients.
Carrasco I; Arias A; Benítez-Gutiérrez L; Lledó G; Requena S; Cuesta M; Cuervas-Mons V; de Mendoza C
J Med Virol; 2018 Mar; 90(3):532-536. PubMed ID: 28990680
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.
Aissa Larousse J; Trimoulet P; Recordon Pinson P; Tauzin B; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
Virol J; 2015 Jun; 12():84. PubMed ID: 26047611
[TBL] [Abstract][Full Text] [Related]
19. Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates.
Bagaglio S; Uberti-Foppa C; Olgiati A; Messina E; Hasson H; Ferri C; Morsica G
Virol J; 2018 Sep; 15(1):144. PubMed ID: 30227876
[TBL] [Abstract][Full Text] [Related]
20. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
